Skip to content

Study · Animal study (in vivo) · rat · 1992

6 results

Insulin-like growth factor I and its variant, des(1-3)IGF-I, improve nitrogen balance and food utilization in rats with renal failure.

Martin AA, Tomas FM, Ballard FJ, Read LC

Mineral and electrolyte metabolism1 Jan 1992Cited by 3 (Europe PMC)

PMID1465072 (opens in a new tab)PepBankPUB-01465072
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, des(1‑3)IGF-I significantly improved food utilization compared with vehicle.

    In plain wordsIn rats, des(1‑3)IGF-I improved food utilization compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseFood utilization
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Food utilization was significantly improved in all three peptide-treated groups, by 13-16% compared with the vehicle-treated nephrectomized group.
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, des(1‑3)IGF-I enhanced nitrogen balance compared with vehicle.

    In plain wordsIn rats, des(1‑3)IGF-I improved nitrogen balance compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseNitrogen balance
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Also, nitrogen balance was enhanced, particularly in the des(1-3)IGF-I group, in which nitrogen excretion was reduced by 24%, with the low- and high-dose IGF-I groups showing 16 and 18% reductions, respectively.
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, des(1‑3)IGF-I reduced nitrogen excretion by 24% compared with vehicle.

    In plain wordsIn rats, des(1‑3)IGF-I reduced nitrogen excretion compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseNitrogen excretion
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Measurements

    Nitrogen excretion reduction
    24%
    des(1-3)IGF-I group

    Source sentences

    Summary
    Also, nitrogen balance was enhanced, particularly in the des(1-3)IGF-I group, in which nitrogen excretion was reduced by 24%, with the low- and high-dose IGF-I groups showing 16 and 18% reductions, respectively.
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, des(1‑3)IGF-I significantly reduced serum urea by 25% compared with vehicle.

    In plain wordsIn rats, des(1‑3)IGF-I reduced serum urea compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseSerum urea
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Measurements

    Serum urea reduction
    25%
    des(1-3)IGF-I group

    Source sentences

    Summary
    Serum urea levels were significantly decreased, by 25%, in the des(1-3)IGF-I group, with 20 and 17% reductions being observed in the low- and high-dose IGF-I groups.
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, des(1‑3)IGF-I significantly attenuated muscle protein degradation compared with vehicle.

    In plain wordsIn rats, des(1‑3)IGF-I reduced muscle protein degradation compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseMuscle protein degradation
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Muscle protein degradation was found to be significantly attenuated with des(1-3)IGF-I treatment but was not significantly affected in the two IGF-I-treated groups.
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In nephrectomized rats, IGF peptide treatment including des(1‑3)IGF-I did not alter carcass composition.

    In plain wordsIn rats, IGF peptide treatment including des(1‑3)IGF-I did not change carcass composition compared with vehicle.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeCarcass composition
    Study

    ratn = 16

    Rats following 5/6 nephrectomy
    Comparator
    Vehicle-treated nephrectomized rats
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.9 mg/kg/BW/day · subcutaneous osmotic pump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    While carcass composition was not altered with IGF peptide treatment,
    1 context sentence
    Summary · context
    Four groups of rats were subjected to 5/6 nephrectomy (n = 8 per group) and treated for 7 days with IGF-I (0.9 or 2.2 mg/kg BW/day), des(1-3)IGF-I (0.9 mg/kg/BW/day), or vehicle (0.1 M acetic acid) administered subcutaneously by osmotic pump.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.